Abstract Relapsing polychondritis (RP) is a rare disorder, often requiring high doses of immunosuppressive therapy to control its potentially life-threatening consequences. The advent of biological agents has added to the armamentarium available to treat RP, but the lack of controlled trials, along with the small numbers of patients and disease heterogeneity means that new therapies are prescribed without the beneWts of rigorous clinical research. Thus, information on individual cases is of value in expanding our knowledge of the use of biologic agents in rare conditions. We report on the use of rituximab in a patient who subsequently developed catastrophic aortic incompetence, and we review the literature in relation to the use of this drug in RP.
The eVectiveness of biological agents in the treatment of inXammatory diseases has resulted in improved understanding of target-orientated therapy and given us new insights into the pathogenesis of rare autoimmune conditions. Relapsing polychondritis (RP) is an uncommon and potentially devastating disease, often requiring very highsteroid doses to control its destructive inXammatory processes. Recent case reports have described the use of several biological agents in the treatment of refractory RP. Despite the conXicting results, such reports contribute towards our knowledge of a disease that is too rare to beneWt from the expertise gained from large clinical trials. The following case describes a 45-year-old man, who developed acute, severe aortic incompetence 1 month after treatment with rituximab.
This patient presented to another hospital with chest pain and progressive shortness of breath over a 3-week period. He had been diagnosed with RP 16 years previously and had suVered recurrent sinusitis, deformities of the nose and ears, joint pains and bilateral sensorineural deafness. He was treated at various times throughout the course of his illness with methotrexate, azathioprine, cyclosporine A and inXiximab, in addition to chronic corticosteroid use. Two months previously, he noted worsening joint pains associated with a raised C-reactive protein level (CRP). He was infused with rituximab, his steroid dose was increased and azathioprine was restarted. Investigations revealed a CRP level of 200 mg/l and severe aortic incompetence in the presence of a normal aortic root and good left ventricular function. Additionally, coronary angiography demonstrated stenotic lesions in the left main and right coronary arteries. He was transferred to our institution for urgent repair of his aortic valve and coronary artery grafting which were undertaken successfully. Histologically, the aortic valve had a bland appearance without inXammatory inWltration. Steroids were weaned postoperatively and the azathioprine dose was escalated to therapeutic levels. Eighteen months later, he remains in clinical remission and has regained some hearing following successful cochlear implantation.
Acute aortic incompetence is a rare complication of RP, occurring in approximately 5% of patients [1] . It is more likely to develop in males than females and is associated with a poor prognosis [1] . In one study, 52.6% of patients with RP who require valve replacement died of cardiovascular causes within 4 years of surgery [2] . Valvular incompetence may be secondary to aortic root dilatation or to direct involvement of the aortic valve which may show destructive inXammatory changes or myxomatous degeneration [1, [3] [4] [5] . We were surprised to note the normal histological appearance of the valve in this case, particularly in the absence of aortic root abnormalities. It is possible that the intense immunomodulatory treatment received by the patient prior to his acute cardiac event may have removed inXammatory cells from the area after tissue damage had already occurred. Previous reports have indicated that typical biopsy Wndings in RP include the presence of CD4+ lymphocytes, plasma cells and complement deposition, with associated necrotic or Wbrotic changes in the cartilage [6] . T cells-directed against collagen subtypes have also been demonstrated [6] . In addition, it has been shown that levels of certain proinXammatory cytokines, such as interleukin-8 and macrophage inXammatory protein-1 are signiWcantly elevated in RP compared with rheumatoid arthritis or healthy controls [7] . Although it is not known to what eVect rituximab may have on cardiac or vascular tissue in patients with RP, it is possible that B-cell depletion may suYciently alter the local cytokine milieu or facilitate uninhibited T-cell reactions to collagen subtypes, leading to a predominance of proteolytic enzymes and consequent tissue damage.
Rituximab use in RP has been reported in two recent papers with conXicting results. Leroux et al. [8] described nine patients with refractory disease, all of whom had received prior treatment with corticosteroids and a variety of immunosuppressive agents. Analysis at 6 and 12 months after initiation of rituximab revealed that no patient achieved complete remission, while some were stable and others deteriorated. The authors concluded that rituximab did not result in signiWcant clinical improvement in their patients. In contrast, a subsequent report of rituximab use in RP noted a positive and sustained response in one patient [9] .
There have been a small number of papers in the literature detailing the variable eYcacy of biological therapies in RP. In some instances of refractory and life-threatening disease, these agents resulted in a positive or stable response in the context of prior treatment failures. However, the numbers of treated patients are small and the period of follow-up is generally short. Furthermore, the marked heterogeneity in the phenotypic presentation of such a rare condition means that the eVect of diVerent treatments on clinical outcomes is diYcult to interpret. Additional studies on the cytokine proWles and cellular perturbations of particular disease manifestations may help to guide therapy and improve prognosis in patients with RP.
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